Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Personalized cancer treatment is advancing due to reduced genome sequencing costs and improved vaccine technology.
• Targeting cancer neo-antigens, arising from individual mutations, is a key strategy in developing effective tumor therapies.
• Adeno-associated virus (AAV)-based virus-like particles (VLPs) offer a novel platform for vaccine construction.

Purpose of the Study:

• To develop and evaluate a neo-antigen-specific protein vaccine using an AAV-VLP platform.
• To investigate the role of CD4+ T cell responses mediated by the AAV capsid in cancer treatment.
• To optimize peptide vaccine composition by assessing the necessity of linked MHC class II helper peptides.

Main Methods:

• Construction of a neo-antigen-specific protein vaccine utilizing an AAV-VLP platform.
• Assessment of vaccine efficacy in murine models for cancer prevention and treatment.
• De-linking of major histocompatibility complex (MHC) class II helper peptides from the AAV capsid to formulate an optimized vaccine.

Main Results:

• The AAV-VLP-based neo-antigen vaccine demonstrated effectiveness in preclinical murine models.
• CD4+ T cell responses, influenced by the AAV capsid, were found to be critical for successful melanoma treatment in mice.
• An optimized vaccine formulation, independent of tumor-specific CD4+ T cell responses, proved efficient, highlighting the importance of MHC class II epitopes for CD8+ T cell activity.

Conclusions:

• AAV-VLPs represent a promising platform for developing neo-epitope vaccines for personalized cancer therapy.
• The study underscores the critical role of MHC class II epitopes in eliciting robust CD8+ T cell-mediated anti-tumor immunity.
• Findings support the potential clinical application of AAVLP-based neo-epitope vaccines in treating cancer patients.